Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
Key Highlights
- ➤USPTO grants Cognition a zervimesine composition patent expiring in 2045
- ➤Patent protects zervimesine manufacturing and therapeutic methods across three disorders
- ➤FDA endpoint meeting for DLB registrational program scheduled next week
- ➤Cognition plans new-form zervimesine manufacturing in Q1 2027, pending FDA outcome
Expert Statements
Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics
“The form of zervimesine covered by this patent has an enhanced pharmaceutical and physiochemical profile, which is more suitable for the large-scale manufacturing required for Phase 3 and commercialization.”
Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics
“We have a meeting scheduled with the FDA next week to finalize endpoint selection for our registrational program in dementia with Lewy bodies (DLB). Pending a favorable outcome from this meeting, we plan to begin manufacturing this new form of zervimesine in the first quarter of 2027 for use in our registrational clinical trial.”
PURCHASE, N.Y., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the United States Patent and Trademark Office (USPTO) has granted the company a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), the company's lead drug candidate. The patent has a natural expiration of 2045. Upon zervimesine’s approval by the U.S. Food and Drug Administration (FDA), the patent may be eligible for an extension of up to five additional years.
“The form of zervimesine covered by this patent has an enhanced pharmaceutical and physiochemical profile, which is more suitable for the large-scale manufacturing required for Phase 3 and commercialization,” said Anthony Caggiano, M.D., Ph.D., Cognition’s chief medical officer. “We have a meeting scheduled with the FDA next week to finalize endpoint selection for our registrational program in dementia with Lewy bodies (DLB). Pending a favorable outcome from this meeting, we plan to begin manufacturing this new form of zervimesine in the first quarter of 2027 for use in our registrational clinical trial.”
Get started
Create a free account to read the full story.